Phentermine
Vascular Diseases
National Heart, Lung, and Blood Institute (NHLBI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Vascular Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dolutegravir Augusta University | Phase 4 | BB |
Acetylsalicylic Acid The Second Hospital of Anhui Medical University | Phase 4 | BB |
3-N-BUTYLPHTHALIDE Qianfoshan Hospital | Phase 4 | BB |
Telcagepant Merck Sharp & Dohme LLC | Phase 3 | B |
FLUOXETINE University Health Network, Toronto | Phase 2 | B |
View all 16 →
Same molecule, other indications
Phentermine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →